摘要
目的探讨齐拉西酮治疗精神分裂症的临床疗效及安全性。方法将60例精神分裂症患者随机分为两组，每组30例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察8周。于治疗前及治疗第2周、4周、6周、8周末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降（P〈0．05或0．01）；治疗8周末研究组显效率66．67％、有效率86．67％，对照组分别为63．33％、83．33％，两组疗效差异无显著性（P〉0．05）。两组不良反应均轻微，但研究组不良反应发生率以及锥体外系反应、月经改变、体质量增加发生率均显著低于对照组（P〈0.05）。结论齐拉西酮与利培酮治疗精神分裂症疗效显著，总体疗效相当；但齐拉西酮安全性更高，较少引起体质量增加、月经改变及锥体外系反应，是一种安全有效的新型抗精神病药物。
Objective To explore the efficacy and adverse reactions of ziprasidone in the treatment of schizophrenia. Methods Sixty schizophrenics were randomly divided into two groups of 30 patients each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） , and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2^nd, 4^th, 6^th and 8^th week. Results After treatment, the PANSS total and each factor scores of both groups lowered more significantly compared with pretreatment （P〈0.05 or 0.01） ; at the end of the 8＇h week, obvious effective and effective rates were 66.67% and 86.7% in the research and 63.33% and 83.3% in the control group respectively, which showed no significant differences （P〉0.05） . Adverse reactions of both groups were mild, but the incidences of adverse reactions and those of extrapyramidal symptoms, menstruation changes and weight gain were significantly lower in the research than in the control group （P〈0.05）. Conclusion Both ziprasidone and risperidone are effective and equivalent in schizophrenia; but ziprasidone has higher safety, causes weight gain, menstruation changes and extrapyramidal symptoms less, and is a novel safe and effective antipsychotic.
出处
《临床心身疾病杂志》
CAS
2011年第2期120-121,共2页
Journal of Clinical Psychosomatic Diseases
